A salt crystal form and a free base crystal form of a kinase inhibitor are provided. Specifically, the kinase inhibitor can be a salt crystal form formed by a compound as shown in formula I and different acids, and a free base crystal form thereof.

##STR00001##

A process for preparing a catalyst by selecting an active catalyst and contacting the active catalyst with one or more fluids containing an organic solvent or mixture of organic solvents. In one embodiment, each organic solvent has a dielectric constant within a range of about 5 to about 55 when measured at a temperature of 20 C. to 25 C. The catalyst thus prepared may be used in a process for preparing maleic anhydride.

A process for preparing a catalyst by selecting an active catalyst and contacting the active catalyst with one or more fluids containing an organic solvent or mixture of organic solvents. In one embodiment, each organic solvent has a dielectric constant within a range of about 5 to about 55 when measured at a temperature of 20 C. to 25 C. The catalyst thus prepared may be used in a process for preparing maleic anhydride.

Chemical entities that are effective as kinase inhibitors, pharmaceutical compositions and methods of treatment are disclosed. The chemical entities disclosed specifically inhibit signal transduction and cellular proliferation by modulating the activity of protein kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism. The compounds include a pyrido[3,2-d]pyrimidine scaffold substituted with aromatic and heteroaromatic moieties.

Chemical entities that are effective as kinase inhibitors, pharmaceutical compositions and methods of treatment are disclosed. The chemical entities disclosed specifically inhibit signal transduction and cellular proliferation by modulating the activity of protein kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism. The compounds include a pyrido[3,2-d]pyrimidine scaffold substituted with aromatic and heteroaromatic moieties.

The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

The present invention provides a salt of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals.

The present invention provides a salt of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals.

A salt compound, and methods for mitigating neurodegeneration, effecting, neuroprotection and/or effecting cognition enhancement in a subject using the salt compound are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic salt compound comprising, a nitrate ester.